Current status of endoscopic sleeve gastroplasty: An opinion review  

作　　者：Jiunn-Wei Wang Chih-Yen Chen 

机构地区：[1]Division of Gastroenterology,Department of Internal medicine,Kaohsiung Medical University Hospital,Kaohsiung 80756,Taiwan [2]Department of Medicine,College of Medicine,Kaohsiung Medical University,Kaohsiung 80756,Taiwan [3]Graduate Institute of Clinical Medicine,College of Medicine,Kaohsiung Medical University,Kaohsiung 80756,Taiwan [4]Division of Gastroenterology and Hepatology,Department of Medicine,Taipei Veterans General Hospital,Taipei 11217,Taiwan [5]Endoscopy Center for Diagnosis and Treatment,Taipei Veterans General Hospital,Taipei 11217,Taiwan [6]Faculty of Medicine and Institute of Emergency and Critical Medicine,National Yang-Ming University School of Medicine,Taipei 11217,Taiwan [7]Institutional Review Board,Taipei Veterans General Hospital,Taipei 11217,Taiwan [8]Chinese Taipei Society for the Study of Obesity,Taipei 11031,Taiwan

出　　处：《World Journal of Gastroenterology》2020年第11期1107-1112,共6页世界胃肠病学杂志（英文版）

摘　　要：Bariatric surgeries have been demonstrated to be safe and effective treatment options for morbid obesity patients, but operative risks and high health care costs limit their clinical application. Endoscopic bariatric therapies are emerging as valuable alternatives for patients with doubts about bariatric surgery or ineligible for it. Endoscopic sleeve gastroplasty(ESG), a relatively novel technique of endoscopic bariatric therapies, has gained standing in the past few years. The safety, feasibility, repeatability, and potential for reversibility of ESG have been proven by multicenter studies. Compared to other weight loss strategies, current evidence demonstrates that ESG offers satisfactory efficacy in weight loss. Even though it is inferior to laparoscopic sleeve gastrectomy, it has lower risks of adverse events than surgical interventions and intragastric balloon within oneyear follow-up. Furthermore, ESG may be the ideal weight control strategy for patients who have poor adherence to behavioral interventions. Even so, trends in decreased weight loss effect over time, post-procedure weight regain, postprocedure gut hormone alteration, and possible effects of race and ethnicity on ESG still remain undetermined due to very limited reports and very short followups. Further clinical trials are required to validate and answer these questions.Bariatric surgeries have been demonstrated to be safe and effective treatment options for morbid obesity patients, but operative risks and high health care costs limit their clinical application. Endoscopic bariatric therapies are emerging as valuable alternatives for patients with doubts about bariatric surgery or ineligible for it. Endoscopic sleeve gastroplasty(ESG), a relatively novel technique of endoscopic bariatric therapies, has gained standing in the past few years. The safety, feasibility, repeatability, and potential for reversibility of ESG have been proven by multicenter studies. Compared to other weight loss strategies, current evidence demonstrates that ESG offers satisfactory efficacy in weight loss. Even though it is inferior to laparoscopic sleeve gastrectomy, it has lower risks of adverse events than surgical interventions and intragastric balloon within oneyear follow-up. Furthermore, ESG may be the ideal weight control strategy for patients who have poor adherence to behavioral interventions. Even so, trends in decreased weight loss effect over time, post-procedure weight regain, postprocedure gut hormone alteration, and possible effects of race and ethnicity on ESG still remain undetermined due to very limited reports and very short followups. Further clinical trials are required to validate and answer these questions.

关 键 词：Obesity ENDOSCOPIC BARIATRIC therapy ENDOSCOPIC SLEEVE GASTROPLASTY Laparoscopic SLEEVE GASTRECTOMY Intragastric balloon Behavioral weight loss intervention 

分 类 号：R656.6[医药卫生—外科学]